Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Metabotropic glutamate receptors are G-protein-coupled receptors normally expressed in the central nervous system where they mediate neuronal excitability, synaptic plasticity, and feedback inhibition of neurotransmitter release. However, recent data suggest that these receptors are also expressed and functional in some cancers, most notably melanoma. We detected the expression of metabotropic glutamate receptor-1 (gene: GRM1; protein: mGluR1) in triple negative breast cancer cells and evaluated its role in regulating the pro-proliferative phenotype of these cells. mGluR1 inhibitors (Riluzole or BAY36-7620) inhibited the proliferation of triple negative breast cancer cells in a time- and dose-dependent manner and this inhibition correlated with increased apoptosis as demonstrated by increase in PARP cleavage products and Annexin V staining. mGluR1 knockdown using Lentiviral constructs expressing shRNA targeting GRM1 also inhibited proliferation compared to non-silencing controls. In addition, treatment of mice bearing MDA-MB-231 xenografts with Riluzole or BAY36-7620, by intraperitoneal injection, resulted in a significant reduction in tumor volume of up to 80%. Moreover, Riluzole was effective against triple negative breast cancer xenografts in mice at doses equivalent to those currently being used in humans for the treatment of amyotrophic lateral sclerosis. Our observations implicate mGluR1 and glutamate signaling as a promising new molecular target for the treatment of breast cancer. Even more promising, Riluzole, because it is an oral drug that can be administered with low toxicity, represents a promising approach in the treatment of triple negative breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
G-protein-coupled receptors and signaling networks: emerging paradigms
Marinissen, M. J., & Gutkind, J. S. (2001) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(00)01678-3 · Cited by 1,049
Hou, L., & Klann, E. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0995-04.2004 · Cited by 527
Amyotrophic Lateral Sclerosis: Current and Future Treatment Strategies
Festoff, B. W. (1996) · Drugs · doi:10.2165/00003495-199651010-00004 · Cited by 35
Cited by
Levin, M. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-12-0708 · Cited by 372
Metabolic reprogramming in triple-negative breast cancer
Wang, Z., Jiang, Q., & Dong, C. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0210 · Cited by 248
Voltage-gated sodium channels and metastatic disease
Brackenbury, W. J. (2012) · Channels · doi:10.4161/chan.21910 · Cited by 198
Teicher, B. A., Linehan, W. M., & Helman, L. J. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2587 · Cited by 152
“mGluR1 inhibitors (Riluzole or BAY36-7620) or mGluR1 knockdown can inhibit growth of melanoma and triple negative breast cancer xenografts (17).”
Background
Metadata
- Authors
- Speyer, C. L., Smith, J. S., Banda, M., DeVries, J. A., Mekani, T., & Gorski, D. H.
- Venue
- Breast Cancer Research and Treatment
- Published
- 2011-06-17
- Volume
- 132
- Issue
- 2
- Pages
- 565-573
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W1996280923
- Cited by
- 122
- References
- 3
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. https://app.cochat.ai/papers/10.1007/s10549-011-1624-x
- The paper
- Speyer, C. L., Smith, J. S., Banda, M., DeVries, J. A., Mekani, T., & Gorski, D. H. (2012). Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-011-1624-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.